Sierra Acai Company
Sierra Acai Company
Open 7 Days a Week
MonaVie Independent Distributor
Distributor Training
Shop Online
Enroll Now
Buy Wholesale and maintain an Active status for 2 months and we will refund your $39 Distributor Fee
Friends
Buy Wholesale and maintain an Active status for 2 months and we will refund your $39 Distributor Fee
07-SEPTEMBER-2008 03:17:44 - Benzodiazepine withdrawal syndrome Redirected from Benzodiazepine withdrawal Benzodiazepine withdrawal syndrome Classification and external resources ICD-10 F13..3 Benzodiazepine withdrawal syndrome is caused by stopping benzodiazepines or during dosage reduction of benzodiazepines. Benzodiazepine withdrawal syndrome is the symptoms which appear when a patient who has taken the drug for a period of time stops taking the drug. Benzodiazepine withdrawal is similar to the alcohol withdrawal syndrome and barbiturate withdrawal syndrome. Chronic exposure to benzodiazepines causes physical adaptions in the brain to counteract the drug's effects. This is known as a tolerance and physical dependence. When the drug is removed or dosage reduced in an individual physically dependent on benzodiazepines, numerous withdrawal symptoms both physical and psychological may appear and will remain present until the body reverses the physical dependence by making adaptions to the drug-free environment and thus returning the brain to normal function. Many patients wish to withdraw from benzodiazepines owing to concerns of adverse effects from prolonged use and many people have successfully withdrawn from the drugs world-wide. As a result benzodiazepine dependency and withdrawal have been extensively researched in the medical literature. A summary of the medical literature on benzodiazepines and techniques for withdrawal, combined with the clinical expertise of Professor Heather Ashton in psychopharmacology, psychiatry and the running of a withdrawal clinic for 12 years, has led to a well-known patient's guide: The Ashton Manual.1 With sufficient motivation and the proper approach, almost all patients can successfully withdraw from benzodiazepines. However, long term users who are dependent on benzodiazepines must not be made to stop abruptly, as they are at high risk of a severe and possibly life threatening withdrawal syndrome. A slower withdrawal rate with a gradually tapered dose typically mitigates this risk. Contents 1 Physical dependence and addiction 1.1 Cross tolerance 1.2 The Committee on the Review of Medicines 2 Physiology of withdrawal 3 Withdrawal symptoms 4 Time of appearance and duration 5 High dose withdrawal 6 Benzodiazepine withdrawal management 7 Variations 8 Complications 9 Protracted withdrawal 9.1 Examples 9.2 Effect of flumazenil 10 Cognitive behavioral therapy 11 Detox Controversy 12 See also 13 References 14 External links Physical dependence and addiction Regular use of benzodiazepines at prescribed levels for six weeks was found to produce a significant risk of dependence, with resultant withdrawal symptoms appearing on abrupt discontinuation in a study assessing diazepam and buspirone. However, with abrupt withdrawal after six weeks of treatment with buspirone, no withdrawal symptoms developed.2 Various studies have shown between 20-100% of patients prescribed benzodiazepines at therapeutic dosages long term are physically dependent and will experience withdrawal symptoms.3 Benzodiazepine dependence is a frequent complication when they are prescribed for or taken for longer than four weeks, with physical dependence and withdrawal symptoms being the most common problem, but also occasionally drug-seeking behavior. Withdrawal symptoms include anxiety, perceptual disturbances, distortion of all the senses, dysphoria, and, in rare cases, psychosis, and epileptic seizures. The risk factors for benzodiazepine dependence are long-term use beyond four weeks, use of high doses, and use of potent short-acting benzodiazepines among those with certain pre-existing personality characteristics such as dependent personalities, and those prone to drug abuse.4 Previously, physical dependence on benzodiazepines was largely thought to occur only in people on high-therapeutic-dose ranges, and low- or normal-dose dependence was not suspected until the 1970s; and it wasn't until the early 1980s that it was confirmed.5 However, low-dose dependence is now a recognized clinical disadvantage of benzodiazepines, and severe withdrawal syndromes can occur from these low doses of benzodiazepines even after gradual dose reduction.67 Low dose dependence has now been clearly demonstrated in both animal studies and human studies.89 In an animal study of four baboons on low-dose benzodiazepine treatment, three out of the four baboons demonstrated physical dependence and developed flumazenil-precipitated withdrawal symptoms after only two weeks of low-dose benzodiazepine treatment. Furthermore, the baboons on low-dose therapy did not develop more severe flumazenil-precipitated withdrawal symptoms because low-dose benzodiazepine therapy was continued over a period of 6-10 months, suggesting rapid onset of dependence with benzodiazepines and suggesting that physical dependence was complete after two weeks of chronic, low-dose benzodiazepine treatment.10 In another animal study, physical dependence was demonstrated with withdrawal signs appearing after only seven days of low-dose benzodiazepine treatment, and withdrawal signs appeared after only three days after high-dose treatment, which demonstrated the extremely rapid development of tolerance and dependence on benzodiazepines, at least in baboons. It was also found that previous exposure to benzodiazepines sensitized baboons to the development of physical dependence.11 In humans, chronic, low-therapeutic-dose dependence was demonstrated in experimentally precipitated withdrawal using flumazenil to show physical dependence and withdrawal signs. Withdrawal symptoms experienced by the chronic therapeutic low-dose subjects included increased ratings of dizziness, blurred vision, heart pounding, feelings of unreality, pins and needles, nausea, sweatiness, noises louder than usual, jitteriness, things moving, sensitivity to touch. Healthy control subjects who were not dependent on benzodiazepines exhibited no benzodiazepine withdrawal like effects or notable side effects.12 In another study of 34 low-dose benzodiazepine users, physiological dependence was demonstrated by the appearance of withdrawal symptoms in 100% of those who received flumazenil whereas those receiving placebo experienced no withdrawal signs. It was also found that those dependent on low doses of benzodiazepines with a history of panic attacks were at an increased risk of suffering panic attacks due to flumazenil precipitated benzodiazepine withdrawal.13 It has been estimated that 30-45% of chronic low dose benzodiazepine users are dependent and it has been recommended that benzodiazepines even at low dosage be prescribed for a maximum of 7-14 days to avoid dependence.14 Some controversy remains, however, in the medical literature as to the exact nature of low-dose dependence and the difficulty in getting patients to discontinue their benzodiazepines, with some papers attributing the problem to predominantly drug-seeking behavior and drug craving, whereas other papers have found the opposite, attributing the problem to a problem of physical dependence with drug-seeking and craving not being typical of low-dose benzodiazepine users.1516 Cross tolerance Benzodiazepines share a similar mechanism of action with various sedative compounds that act by enhancing the GABAA receptor. Cross tolerance means that one drug will alleviate the withdrawal effects of another. It also means that tolerance of one drug will result in tolerance of another similarly-acting drug. Benzodiazepines are often used for this reason to detoxify alcohol-dependent patients, and can have life-saving properties in preventing and/or treating severe life-threatening withdrawal syndromes from alcohol, such as delirium tremens. However, although benzodiazepines can be very useful in the acute detoxification of alcoholics, benzodiazepines in themselves act as positive reinforcers in alcoholics, by increasing the desire for alcohol. Low doses of benzodiazepines were found to significantly increase the level of alcohol consumed in alcoholics.17 However, alcoholics dependent on benzodiazepines should not be abruptly withdrawn but be very slowly withdrawn from benzodiazepines as over-rapid withdrawal is likely to produce severe anxiety or panic, which is well known for being a relapse risk factor in alcoholics. There is also cross tolerance between alcohol, the benzodiazepines, the barbiturates, and the nonbenzodiazepine drugs, corticosteroids which all act by enhancing the GABAA receptor's function via modulating the chloride ion channel function of the GABAA receptor.1819202122 The Committee on the Review of Medicines The Committee on the Review of Medicines UK carried out a review into benzodiazepines due to significant concerns of tolerance, drug dependence and benzodiazepine withdrawal problems and other adverse effects. The committee found that benzodiazepines do not have any antidepressant or analgesic properties and are therefore unsuitable treatments for conditions such as depression, tension headaches and dysmenorrhoea. Benzodiazepines are also not beneficial in the treatment of psychosis. The committee also recommended against benzodiazepines being used in the treatment of anxiety or insomnia in children. The committee was in agreement with the Institute of Medicine USA and the conclusions of a study carried out by the White House Office of Drug Policy and the National Institute on Drug Abuse USA that there was little evidence that long term use of benzodiazepine hypnotics were benefitial in the treatment of insomnia due to the development of tolerance. Benzodiazepines tended to lose their sleep promoting properties within 3-14 days of continuous use and in the treatment of anxiety the committee found that there was little convincing evidence that benzodiazepines retained efficacy in the treatment of anxiety after 4 months continuous use due to the development of tolerance. The committee found that the regular use of benzodiazepines caused the development of dependence characterised by tolerance to the therapeutic effects of benzodiazepines and the development of the benzodiazepine withdrawal syndrome including symptoms such as anxiety, apprehension, tremor, insomnia, nausea, and vomiting upon cessation of benzodiazepine use. Withdrawal symptoms tended to develop within 24 hours upon cessation of short acting; and 3-10 days after cessation of longer acting benzodiazepines. Withdrawal effects could occur after treatment lasting only 2 weeks at therapeutic dose levels however withdrawal effects tended to occur with habitual use beyond 2 weeks and were more likely the higher the dose. The withdrawal symptoms may appear to be similar to the original condition. The committee recommended that all benzodiazepine treatment be withdrawn gradually and recommended that benzodiazepine treatment be used only in carefully selected patients and that therapy be limited to short term use only. It was noted in the review that alcohol can potentiate the central nervous system depressant effects of benzodiazepines and should be avoided. The central nervous system depressant effects of benzodiazepines may make driving or operating machinery dangerous and the elderly are more prone to these adverse effects. In the neonate high single doses or repeated low doses have been reported to produce hypotonia, poor sucking, and hypothermia in the neonate and irregularities in the fetal heart. Benzodiazepines should be avoided in lactation. Withdrawal from benzodiazepines should be gradual as abrupt withdrawal from high doses of benzodiazepines may cause confusion, toxic psychosis, convulsions, or a condition resembling delirium tremens. Abrupt withdrawal from lower doses may cause depression, nervousness, rebound insomnia, irritability, sweating, and diarrhea.23 Physiology of withdrawal Withdrawal symptoms are a normal response in individuals who have chronically used benzodiazepines, and a side effect and result of drug tolerance. Symptoms typically emerge when dosage of the drug is reduced. GABA receptors are the most common receptor system in the central nervous system and use of benzodiazepines has a profound effect on almost every aspect of brain and body function, either directly or indirectly. Benzodiazepines cause a decrease in norepinephrine noradrenaline, serotonin, acetylcholine and dopamine. These neurotransmitters are needed for normal memory, mood, muscle tone and coordination, emotional responses, endocrine gland secretions, heart rate and blood pressure control. With chronic benzodiazepine use, tolerance develops rapidly to most of its effects, so that when benzodiazepines are withdrawn, various neurotransmitter systems go into overdrive due to the lack of inhibitory GABA-ergic activity. Withdrawal symptoms then emerge as a result, and persist until the nervous system physically reverses the adaptions physical dependence which have occurred in the CNS. Withdrawal symptoms typically consist of a mirror image of the drug's effects: sedative effects and suppression of REM and SWS stages of sleep can be replaced by insomnia, nightmares, and hypnogogic hallucinations; its antianxiety effects are replaced with anxiety and panic; muscle relaxant effects are replaced with muscular spasms or cramps; and anticonvulsant effects with seizures, especially in cold turkey or overly-rapid withdrawal. Clinical trials have shown that benzodiazepines cause an extremely rapid development of tolerance and dependence. Withdrawal symptoms including rebound insomnia and rebound anxiety occurs after only 7 days administration of benzodiazepines.24 Another trial demonstrated rebound withdrawal effects after only 18 nights use of lorazepam as a benzodiazepine hypnotic.25 Rebound day time anxiety, tension develops after only 7 days use of short acting benzodiazepine hypnotics. On withdrawal of benzodiazepines after 7 nights use, withdrawal related insomnia rebounds worse than baseline.2627 Day time withdrawal symptoms are commonly associated with triazolam. This is due to its very short half life. After only 10 nights of triazolam use patients report anxiety, become distressed, weight loss, panics and depression, felt unreal, and develop paranoia. These reactions occurred more commonly with triazolam than lormetazepam which has an intermediate half life. Thus the more short acting a benzodiazepine hypnotic the more severe the day time withdrawal symptoms.28 Patients consuming who are physically dependent on short acting anxiolytic benzodiazepines may experience what is known as interdose withdrawal. Interdose withdrawal are withdrawal symptoms which occur between doses when the previous dose wears off. This can lead to withdrawal symptoms such as rebound anxiety between doses and craving for the next dose of short acting benzodiazepine.12930 Withdrawal symptoms Some of the withdrawal symptoms are identical to the symptoms for which the medication was originally prescribed. The ability to determine the difference between relapse and rebound is very important during the withdrawal phase and can often lead to a misdiagnosis. For this reason, many experts agree that after withdrawal from long term or even fairly short term use of benzodiazepine drugs, at least six months should have elapsed prior to re-evaluating the symptoms and updating a diagnosis. Common symptoms include: Electric shocks31 Muscular spasms, cramps or fasciculations32 Insomnia33 Headache34 Rebound REM sleep35 Hyperosmia36 Metallic taste36 Photophobia36 Paranoia36 Hypnagogia-hallucinations37 Nausea and vomiting33 Nightmares33 Anxiety, possible panic attacks34 Impaired concentration34 Elevation in blood pressure38 Tachycardia39 Hypertension40 Postural hypotension33 Depression can be severe41, possible suicidal ideation Tremor42 Perspiration34 Loss of appetite and weight loss43 Dysphoria4445 Depersonalization4647 Derealisation Feelings of unreality48 Tinnitus49 Paraesthesia4736 Visual disturbances47 Gastrointestinal problems Stomach and abdomen50 An abrupt or over-rapid discontinuation of benzodiazepines may result in a more serious and very unpleasant withdrawal syndrome that may additionally result in: Convulsions, which may result in death5152 Catatonia, which may result in death53 Coma54 rare Temporal lobe epilepsy31 muscular spasms or cramps, fasciculations32 Suicide1 Attempted suicide47 Suicidal ideation55 Self harm47 Hyperthermia33 Delusions56 Homicidal ideation57 Violence58 Post Traumatic Stress Disorder1 Psychosis59 Confusion60 Mania61 Effects similar to delirium tremens6263 Time of appearance and duration Withdrawal symptoms can occur whilst on a stable dose of benzodiazepines due to the tolerance withdrawal phenomenon, where the body experiences withdrawal effects and craves increasing doses to feel normal which can lead to dosage escalation, but most often withdrawal symptoms occur during dosage reduction. Onset of the withdrawal syndrome from long half-life benzodiazepines might be delayed for up to 3 weeks, although withdrawal symptoms from short-acting benzodiazepines often presents early usually within 24-48 hours.64 The acute benzodiazepine withdrawal syndrome generally lasts for about 2 months but clinically significant withdrawal symptoms may persist, although gradually declining, for many months or even several years. The severity and length of the withdrawal syndrome is likely determined by various factors including rate of tapering, length of use of benzodiazepines and dosage size and possibly genetic factors.65 As withdrawal progresses after some weeks or months many individuals begin to experience windows of normality, where they experience little or no symptoms. These windows can last for hours or days. Over time these windows increase in frequency until withdrawal symptoms completely abate. A theory for this phenomenon is the affinity for GABA of the benzodiazepine receptor is switching from one state to the other as tolerance to the drug is beginning to reverse.1 High dose withdrawal Abrupt withdrawal from very high doses can cause severe withdrawal effects. Withdrawal from high dose abuse of nitrazepam have caused severe hypoperfusion of the whole brain with diffuse slow activity on EEG. After withdrawal, abnormalities in hypofrontal brain wave patterns persist beyond the withdrawal syndrome which suggested organic brain damage occurs from chronic high dose abuse of benzodiazepines.66 Benzodiazepine withdrawal management See also Benzodiazepine half life and equivalency table The slower the withdrawal rate the less intense the withdrawal symptoms and there is strong anecdotal evidence that slower withdrawal rates decrease the risk of developing a severe protracted benzodiazepine withdrawal syndrome. The rate of withdrawal preferably utilising either diazepam or chlordiazepoxide for their long half lifes and low potency dose forms, is best carried out according to the withdrawing patient's body response to dose cuts. The British National Formulary, a medical guidance book which is issued to all British doctors, states that it is better to withdraw too slowly rather than too quickly from benzodiazepines. People withdrawing from benzodiazepines should be careful that they do not supplement their benzodiazepines for drugs which work through the same or similar GABA mechanism including alcohol, barbiturates and the nonbenzodiazepine Z drugs otherwise they may keep the dependency going. Fluoroquinolone antibiotics have been noted by Professor Heather Ashton and confirmed in a study as often causing serious complications in patients taking or undergoing withdrawal from benzodiazepines. This is probably the result of the GABA antagonistic effect of fluoroquinolones. Fluoroquinolones have also been found to competitively displace benzodiazepines from benzodiazepine receptors which can precipitate acute withdrawal symptoms in benzodiazepine dependent subjects. A study reported higher than usual CNS toxicity from fluoroquinolones in subjects who were dependent on or in withdrawal from benzodiazepines. Of the general public 1 - 4% of the public will experience CNS toxicity from fluoroquinolones which may be severe. The incidence of severe CNS toxicity occurs significantly more frequently in the benzodiazepine dependent population. The CNS adverse reactions from fluoroquinolones were similar to those seen in benzodiazepine withdrawal and persisted for weeks or months before subsiding. The symptoms included depression, anxiety, psychosis, paranoia, severe insomnia, parathesia, tinnitus, hypersensitivity to light and sound, tremors, status epilepticus, suicidal thoughts and suicide attempt. The study confirmed that fluoroquinolone CNS toxicity can be serious, occurs more frequently in benzodiazepine dependent subjects and concluded that fluoroquinolone antibiotics should be contraindicated in patients who are dependent on or in benzodiazepine withdrawal.16768 Antipsychotics should be avoided during benzodiazepine withdrawal as they tend to aggravate withdrawal symptoms, including convulsions.6970 The addition of an SSRI antidepressant has been found to have little value in the treatment of benzodiazepine withdrawal.71 Once the benzodiazepine addicted or physically dependent individual has successfully withdrawn from benzodiazepines they should avoid taking even occasionally benzodiazepines or cross tolerant drugs such as alcohol, barbiturates or the nonbenzodiazepines for between four months and two years, depending on personal biochemisty. This is because tolerance to benzodiazepines has been demonstrated to be still present in patients who have discontinued benzodiazepines between four months and two years post withdrawal. In these patients even once off low dose re-exposures to benzodiazepines typically resulted in a reactivation of the tolerance and benzodiazepine withdrawal syndrome.72 Detoxification of a benzodiazepine dependent individual is often carried out using an equivalent dose of either diazepam or chlordiazepoxide to the benzodiazepine the individual is dependent on and by reducing in steps of 10% every 2-4 weeks depending on the severity of the dependency and the patient's response to reductions. However, if withdrawal is carried out slow enough and preferably using an equivalent dose of diazepam or chlordiazepoxide to withdraw, many benzodiazepine dependent patients find that they experience little or sometimes no withdrawal when it comes time to come off the last 0.5 mg dose of diazepam or 5 mg dose of chlordiazepoxide. Those who have withdrawn slow enough but still experience withdrawal effects typically find that their withdrawal symptoms have largely disappeared after a few months. It is strongly recommended that during benzodiazepine withdrawal that the drug used is diazepam Valium or chlordiazepoxide Librium as they has a longer half-life than most other benzodiazepines such as Lorazepam Ativan and hence a smoother withdrawal.73 It is virtually impossible to withdraw successfully if the addiction is to a short to intermediate half-life hypnotic benzodiazepine such as Temazepam Normison, the toll on the body is too high and debilitating.74 It is also critical that whilst the early and mid part of withdrawal should be managed with a 1 mg for diazepam or 5 mg for chlordiazepoxide reduction every 2 weeks, the reduction down to 5 mg for diazepam or 12.5 mg for chlordiazepoxide daily is a key milestone. From 5 mg down to 0 mg for diazepam or 12.5 mg to 0 mg for chlordiazepoxide a taper of 0.5mg for diazepam or 1.25 mg for chlordiazepoxide reduction every three weeks makes this much more tolerable on the mind and body. Usually, for most people, once off the drug, a sense of relief and well-being can be felt after 2-3 months of total abstinence. It is very important to use the correct benzodiazepine equivalencies when switching benzodiazepines either therapeutically or in the management of withdrawal. This importance was illustrated in a case reported in the medical literature of a man who had been taking doses of lorazepam and alprazolam equivalent of 60 mg of diazepam. He was then switched from the lorazepam and alprazolam to only 7 mg of diazepam per day. Within 36 hours the patient developed somatic symptoms and became convinced that he had an underlying pathology and impulsively attempted suicide by stabbing himself in the abdomen causing himself serious injury requiring emergency surgery. His symptoms and suicide attempt were diagnosed by his GP and psychiatrist as benzodiazepine withdrawal. The patient again tried to withdraw from benzodiazepines but again attempted suicide by inflicting serious stab wounds to his neck and chest which resulted in admittance to a psychiatric unit. The author warned that self harm can be a feature of benzodiazepine withdrawal.47 Withdrawal from stronger hypnotics such as temazepam, flunitrazepam, nitrazepam, triazolam, flutoprazepam, lormetazepam, midazolam, brotizolam and similar hypnotic benzodiazepines should be treated with higher dose diazepam, clonazepam, or even phenobarbital to avoid life threatening seizures, delirium, psychotic episodes, and suicidal ideation. Variations Some people experience little or no withdrawal when stopping long term benzodiazepine usage. It is not known for sure why there is such a variation between patients but recent research in animals suggests that withdrawal from sedative hypnotic drugs may be influenced by a genetic component.1 As withdrawal progresses patients often find that their physical and mental health improves with improved mood and improved cognition. Complications Over-rapid withdrawal and lack of explanation and failure to reassure individuals that what they are experiencing is withdrawal symptoms and is temporary have led some people to experience increased panic and fears that they are going mad, with some people developing Post Traumatic Stress Disorder as a result. A slow withdrawal regime coupled with reassurance seems to improve the outcome for individuals undergoing benzodiazepine withdrawal.1 Protracted withdrawal Benzodiazepine dependence is a potentially clinically serious condition and its withdrawal syndrome is complex and often protracted in time course.75 Protracted withdrawal symptoms refers to symptoms persisting for a protracted time, perhaps year or more. Patients who experience protracted withdrawal from benzodiazepines, which more commonly occurs from over-rapid withdrawal, can be reassured that the evidence shows that symptoms do continue to fade and return to normal over a period of many months or several years. A figure of 10-15% of patients withdrawing from benzodiazepines may experience a protracted withdrawal syndrome.37 There is strong anecdotal evidence that a slow-withdrawal rate significantly reduces the risk of a protracted and/or severe withdrawal state. About 10-15% of people who discontinue benzodiazepines develop protracted withdrawal syndrome. There is no known cure for protracted benzodiazepine withdrawal syndrome except time.76 The post withdrawal syndrome may linger for many months in 10-15% of people and for a smaller number of unfortunate patients for several years. Studies following people up beyond the initial acute withdrawal stage have shown that for many patients symptoms continue to improve the longer they stay off the drug, often to the point where they can eventually resume their normal lives even after years of incapacity imposed by chronic benzodiazepines. The causes of persisting benzodiazepine withdrawal symptoms are a combination of pharmacological factors such as persisting drug induced receptor changes, psychological factors both caused by the drug and separate from the drug and possibly in some cases, particularly high dose users structural brain damage.77 Disturbances in mental function can persist for several months or sometimes longer. Psychotic depression persisting for more than a year following benzodiazepine withdrawal has been documented in the medical literature. The patient had no prior psychiatric history. The symptoms reported in the patient included, major depressive disorder with psychotic features, including persistent depressed mood, poor concentration, decreased appetite, insomnia, anhedonia, anergia and psychomotor retardation. The patient also had paranoid ideation believing she was being poisoned and persecuted by co-employees, and sensorary hallucinations. Symptoms developed after abrupt withdrawal of chlordiazepoxide and persisted for 14 months. Various psychiatric medications were trialed which were unsuccessful in alleviating the symptomatology. Symptoms were completely relieved by recommencing chlordiazepoxide for irritable bowel syndrome 14 months later.78 Sensorary withdrawal related disturbances which can be acute or protracted in duration and are among the clinical features of the benzodiazepine withdrawal syndrome. Protracted tinnitus has been found to be a complication of discontinuation of benzodiazepines with tinnitus persisting for many months or up to a year or more after discontinuation of therapeutic doses of benzodiazepines. Appearance of the tinnitus occurs during dose reduction or discontinuation of benzodiazepines and is alleviated by recommencement of benzodiazepines.7949 Neuropsychological testing of a group of patients with persistent benzodiazepine withdrawal symptoms found that psychophysiological markers differed from normal anxiety markers. The study of the group of patients concluded that protracted withdrawal symptoms were a genuine iatrogenic condition caused by the long term prescription of benzodiazepines.80 Hoffmann-La Roche pharmaceutical company, the manufacturer of clonazepam, in a 2007 product information publication, acknowledges the existence of protracted benzodiazepine withdrawal syndromes and recommends that its product flumazenil is not used to treat protracted benzodiazepine withdrawal syndromes.81 Examples Some common protracted withdrawal symptoms include: cognitive deficits, gastrointestinal complaints, insomnia, tinnitus, paraesthesiae tingling and numbness, pain usually in limbs and extremities, muscle pain, weakness, tension, painful tremor, shaking attacks, jerks, and blepharospasm. Effect of flumazenil A study into the effects of the benzodiazepine receptor antagonist, flumazenil, on benzodiazepine withdrawal symptoms persisting after withdrawal was carried out by Lader and Morton. Study subjects had been benzodiazepine-free for between one month and five years, but all reported persisting withdrawal effects to varying degrees. Persistent symptoms included clouded thinking, tiredness, muscular symptoms such as neck tension, cramps and shaking and the characteristic perceptual symptoms of benzodiazepine withdrawal, namely, pins and needles, burning skin, pain and subjective sensations of bodily distortion. Therapy with 0.2-2 mg of flumazenil intravenously was found to decrease these symptoms in a placebo controlled study. This is of interest as benzodiazepine receptor antagonists are neutral and have no clinical effects. The author of the study suggested that the most likely explanation is that past benzodiazepine use and subsequent tolerance had locked the conformation of the GABA-BZD receptor complex into an inverse agonist conformation, and that the antagonist flumazenil resets benzodiazepine receptors to their original sensitivity. Flumazenil was found in this study to be a successful treatment for protracted benzodiazepine withdrawal syndrome, but it was noted that further research is required.82 Cognitive behavioral therapy Nitrazepam, temazepam and zopiclone are the most frequently prescribed hypnotics in the United Kingdom. Hypnotic drugs are of poor value for the management of chronic insomnia. Hypnotic drug consumption has been shown to reduce work performance, increase absenteeism, increase road traffic accidents, increased morbidity, increase mortality and is associated with an increased incidence of deliberate self harm. In the elderly, increases in falls and fractures associated with sedative hypnotic drug use has been found. It is widely accepted that hypnotic drug usage beyond 4 weeks is undesirable for all age groups of patients. Many continuous hypnotic users exhibit disturbed sleep as a consequence of tolerance but experience worsening rebound or withdrawal insomnia when the dose is reduced too quickly which compounds the problem of chronic hypnotic drug use. Cognitive behavioural therapy has been found to be more effective for the long term management of insomnia than sedative hypnotic drugs. No formal withdrawal programs for benzodiazepines exists with local providers in the UK. Meta-analysis of published data on psychological treatments for insomnia show a success rate between 70 and 80%. A large scale trial utilising cognitive behavioural therapy in chronic users of sedative hypnotics including nitrazepam, temazepam and zopiclone found CBT to be a significantly more effective long term treatment for chronic insomnia than sedative hypnotic drugs. Persisting improvements in sleep quality, sleep onset latency, increased total sleep, improvements in sleep efficiency, significant improvements in vitality, physical and mental health at 3, 6 and 12 month follow up was found in those receiving cognitive behavioural therapy. A marked reduction in total sedative hypnotic drug use was found in those receiving CBT, with 33% reporting zero hypnotic drug use. Age has been found not to be a barrier to successful outcome of CBT. It was concluded that CBT for the management of chronic insomnia was flexible, practical and a cost effective treatment and it was also concluded that CBT leads to a reduction of benzodiazepine drug intake in a significant number of patients.83 Detox Controversy In some instances, a Detox or other inpatient facility will take a patient off a benzodiazepine cold turkey - replacing it with a short taper of Phenobarbital a barbiturate to prevent seizures. This method of coming off a benzodiazepine is highly controversial and often called barbaric. Most Physicians and medical authorities agree that in the majority of cases a slow taper is preferred to a rapid taper or cold turkey withdrawal from a benzodiazepine. However, more recent research is showing promise with the use of flumazenil in the management of benzodiazepine detoxification. Flumazenil has been found to stimulate the reversal of tolerance and the normalisation of receptor function. Flumazenil stimulates the upregulation and reverses the uncoupling of benzodiazepine receptors to the GABA receptor thereby reversing tolerance and reducing withdrawal symptoms and relapse rates.84 See also Alcohol withdrawal syndrome Benzodiazepine equivalence Benzodiazepine References ^ a b c d e f g Professor Heather Ashton 2002. Benzodiazepines: How They Work and How to Withdraw. ^ Murphy SM, Owen R, Tyrer P. 1989. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone.. The British Journal of Psychiatry : the journal of mental science. 154: 529-34. PMID 2686797. ^ Ashton, CH 1997 publisher= Cambridge University Press. Benzodiazepine Dependency, in A Baum, S. Newman, J. Weinman, R. West, C. McManus: Cambridge Handbook of Psychology Medicine, 376-80. Retrieved on 03. ^ Marriott S, Tyrer P. Aug 1993. Benzodiazepine dependence. Avoidance and withdrawal.. Drug safety : an international journal of medical toxicology and drug experience. 9 2: 93-103. PMID 8104417. ^ Lader M. 1991. History of benzodiazepine dependence.. Journal of substance abuse treatment. 8 1-2: 53-9. doi:10.1016/0740-54729190027-8. PMID 1675692. ^ Lader M. Dec 1987. Long-term anxiolytic therapy: the issue of drug withdrawal.. The Journal of clinical psychiatry. 48: 12-6. PMID 2891684. ^ Miura S; Murasaki M Mar 1992. The future of 5-HT1A receptor agonists. Aryl-piperazine derivatives.. Progress in neuro-psychopharmacology biological psychiatry. 16 6: 833-45. doi:10.1016/0278-58469290103-L. PMID 1355301. ^ Lucki I; Kucharik RF. 1990. Increased sensitivity to benzodiazepine antagonists in rats following chronic treatment with a low dose of diazepam.. Psychopharmacology. 102 3: 350-6. doi:10.1007/BF02244103. PMID 1979180. ^ Rickels K; Case WG, Schweizer EE, Swenson C, Fridman RB. 1986. Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients.. Psychopharmacology bulletin. 22 2: 407-15. PMID 2877472. ^ Kaminski BJ; Sannerud CA, Weerts EM, Lamb RJ, Griffiths RR. Jul 2003. Physical dependence in baboons chronically treated with low and high doses of diazepam.. Behavioural pharmacology. 14 4: 331-42. PMID 12838039. ^ Lukas SE; Griffiths RR. 20. Precipitated diazepam withdrawal in baboons: effects of dose and duration of diazepam exposure.. European journal of pharmacology. 100 2: 163-71. doi:10.1016/0014-29998490218-8. PMID 6428921. ^ Mintzer MZ; Stoller KB, Griffiths RR. Nov 1999. A controlled study of flumazenil-precipitated withdrawal in chronic, low-dose benzodiazepine users. 147 2: 200-9. PMID 10591888. ^ Bernik MA; Gorenstein C, Vieira Filho AH. 1998. Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users.. Journal of psychopharmacology Oxford, England. 12 2: 146-50. PMID 9694026. ^ Meier PJ; Ziegler WH, Neftel K. 19. Benzodiazepine--practice and problems of its use. Schweizerische medizinische Wochenschrift. 118 11: 381-92. PMID 3287602. ^ Linden M; Bär T, Geiselmann B. May 1998. Patient treatment insistence and medication craving in long-term low-dosage benzodiazepine prescriptions.. Psychological medicine. 28 3: 721-9. doi:10.1017/S0033291798006734. PMID 9626728. ^ Tyrer P. 1993. Benzodiazepine dependence: a shadowy diagnosis.. Biochemical Society symposium. 59: 107-19. PMID 7910738. ^ Poulos CX; Zack M. 2004. Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers.. Behavioural pharmacology. 15 7: 503-12. PMID 15472572. ^ Khanna JM, Kalant H, Weiner J, Shah G 1992. Rapid tolerance and cross-tolerance as predictors of chronic tolerance and cross-tolerance. Pharmacol. Biochem. Behav. 41 2: 355-60. PMID 1574525. ^ World Health Organisation - Assessment of Zopiclone ^ Allan AM, Baier LD, Zhang X 1992. Effects of lorazepam tolerance and withdrawal on GABAA receptor-operated chloride channels. J. Pharmacol. Exp. Ther. 261 2: 395-402. PMID 1374467. ^ Rooke KC. 1976. The use of flurazepam dalmane as a substitute for barbiturates and methaqualone/diphenhydramine mandrax in general practice. J Int Med Res 4 5: 355-9. PMID 18375. ^ Reddy DS; Rogawski MA Dec 2000. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J Pharmacol Exp Ther 295 3: 1241-8. PMID 11082461. ^ Committee on the Review of Medicines 29. Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines. pdf. Br Med J. 280 6218: 910-2. PMID 7388368. ^ Scharf MB; Kales A, Bixler EO, Jacoby JA, Schweitzer PK Feb 1982. Lorazepam-efficacy, side effects, and rebound phenomena. Clin Pharmacol Ther 31 2: 175-9. PMID 6120058. ^ Walsh JK; Schweitzer PK, Parwatikar S Oct 1983. Effects of lorazepam and its withdrawal on sleep, performance, and subjective state. Clin Pharmacol Ther 34 4: 496-500. PMID 6617072. ^ Kales A; Bixler EO, Soldatos CR, Jacoby JA, Kales JD 1986. Lorazepam: effects on sleep and withdrawal phenomena. Pharmacology 32 3: 121-30. doi:10.1159/000138160. PMID 3960963. ^ Bonnet MH; Arand DL Mar 1999. The use of lorazepam TID for chronic insomnia. Int Clin Psychopharmacol 14 2: 81-9. doi:10.1097/00004850-199903000-00004. PMID 10220122. ^ Adam K; Oswald I May 1989. Can a rapidly-eliminated hypnotic cause daytime anxiety?. Pharmacopsychiatry 22 3: 115-9. PMID 2748714. ^ Herman JB; Rosenbaum JF, Brotman AW Jun 1987. The alprazolam to clonazepam switch for the treatment of panic disorder. J Clin Psychopharmacol 7 3: 175-8. doi:10.1097/00004714-198706000-00012. PMID 3597803. ^ Herman JB; Brotman AW, Rosenbaum JF Oct 1987. Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. J Clin Psychiatry 48 Suppl: 22-8. PMID 2889722. ^ a b Shader RI; Greenblatt DJ 1981. The use of benzodiazepines in clinical practice. Br J Clin Pharmacol 11 Suppl 1: 5S-9S. PMID 6133535. ^ a b Kliniska Färdigheter: Informationsutbytet Mellan Patient Och Läkare, LINDGREN, STEFAN, ISBN 91-44-37271-X Swedish ^ a b c d e Bismuth C; Le Bellec M, Dally S, Lagier G 28. Benzodiazepine physical dependence. 6 cases author's transl. Nouv Presse Med 9 28: 1941-5. PMID 6106922. ^ a b c d Pétursson H Nov 1994. The benzodiazepine withdrawal syndrome. Addiction 89 11: 1455-9. doi:10.1111/j.1360-0443.1994.tb03743.x. PMID 7841856. ^ Pagel JF; Parnes BL Jun 2001. Medications for the Treatment of Sleep Disorders: An Overview PDF. Prim Care Companion J Clin Psychiatry 3 3: 118-125. PMID 15014609. ^ a b c d e Pelissolo A; Bisserbe JC Mar-Apr 1994. Dependence on benzodiazepines. Clinical and biological aspects. Encephale 20 2: 147-57. PMID 7914165. ^ a b Professor Heather Ashton 2004. Protracted Withdrawal Symptoms From Benzodiazepines. Comprehensive Handbook of Drug Alcohol Addiction. ^ Mintzer MZ; Griffiths RR Mar 2005. Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure. Psychopharmacology Berl 178 2-3: 259-67. doi:10.1007/s00213-004-2009-1. PMID 15452683. ^ van Engelen BG; Gimbrere JS, Booy LH May 1993. Benzodiazepine withdrawal reaction in two children following discontinuation of sedation with midazolam. Ann Pharmacother 27 5: 579-81. PMID 8347907. ^ Biswas AK; Feldman BL, Davis DH, Zintz EA 2005. Myocardial ischemia as a result of severe benzodiazepine and opioid withdrawal. Clin Toxicol Phila 43 3: 207-9. PMID 15902797. ^ Lader M 1994. Anxiety or depression during withdrawal of hypnotic treatments. J Psychosom Res 38 Suppl 1: 113-23 discussion 118-23. doi:10.1016/0022-39999490142-2. PMID 7799243. ^ Mellor CS; Jain VK 1. Diazepam withdrawal syndrome: its prolonged and changing nature PDF. Can Med Assoc J 127 11: 1093-6. PMID 7139456. ^ Pecknold JC 1993. Discontinuation reactions to alprazolam in panic disorder. J Psychiatr Res 27 Suppl 1: 155-70. doi:10.1016/0022-39569390025-W. PMID 8145176. ^ Mendelson WB; Weingartner H, Greenblatt DJ, Garnett D, Gillin JC 1982. A clinical study of flurazepam. Sleep 5 4: 350-60. PMID 6761826. ^ Schöpf J Jan 1983. Withdrawal phenomena after long-term administration of benzodiazepines. A review of recent investigations. Pharmacopsychiatria 16 1: 1-8. PMID 6131447. ^ Terao T; Yoshimura R, Terao M, Abe K. 15. Depersonalization following nitrazepam withdrawal. Biol Psychiatry 31 2: 212-3. doi:10.1016/0006-32239290209-I. PMID 1737083. ^ a b c d e f Neale G; Smith AJ May 2007. Self-harm and suicide associated with benzodiazepine usage. Br J Gen Pract 57 538: 407-8. pubmed central. PMID 17504594. ^ Mintzer MZ; Stoller KB, Griffiths RR Nov 1999. A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users. Psychopharmacology Berl 147 2: 200-9. doi:10.1007/s002130051161. PMID 10591888. ^ a b Beeley L 15. Benzodiazepines and tinnitus PDF. BMJ 302 6790: 1465. PMID 2070121. ^ Loeb P; Adnet P, Boittiaux P, Forget AP, Mille FX. 1997. Benzodiazepine withdrawal presenting as pseudo-surgical abdominal pain. Annales françaises d'anesthèsie et de rèanimation. 16 5: 521-2. doi:10.1093/bja/aei040. PMID 9750606. ^ Metten P, Crabbe JC 1999. Genetic determinants of severity of acute withdrawal from diazepam in mice: commonality with ethanol and pentobarbital. Pharmacol. Biochem. Behav. 63 3: 473-9. PMID 10418790. ^ Haque W, Watson DJ, Bryant SG 1990. Death following suspected alprazolam withdrawal seizures: a case report. Texas medicine 86 1: 44-7. PMID 2300914. ^ Rosebush PI; Mazurek MF 1996. Catatonia after benzodiazepine withdrawal. Journal of clinical psychopharmacology 16 4: 315-9. PMID 8835707. ^ de Bard ML Jan 1979. Diazepam withdrawal syndrome: a case with psychosis, seizure, and coma. Am J Psychiatry 136 1: 104-5. PMID 103443. ^ Einarson A; Selby P, Koren G Jan 2001. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling PDF. J Psychiatry Neurosci 26 1: 44-8. PMID 11212593. ^ Keshavan MS; Moodley P, Eales M, Joyce E, Yeragani VK Oct 1988. Delusional depression following benzodiazepine withdrawal. Can J Psychiatry 33 7: 626-7. PMID 3197017. ^ Risse SC; Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA. 1990. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder.. The Journal of clinical psychiatry. 51 5: 206-9. PMID 2335496. ^ Citrome L; Volavka J. 1999. Violent patients in the emergency setting.. The Psychiatric clinics of North America. 22 4: 789-801. doi:10.1016/S0193-953X0570126-X. PMID 10623971. ^ Peh LH; Mahendran R Feb 1989. Psychiatric complications of Erimin abuse. Singapore Med J 30 1: 72-3. PMID 2595393. ^ Uhlenhuth EH; Starcevic V, Qualls C, Antal EJ, Matuzas W, Javaid JI, Barnhill J Oct 2006. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs. J Clin Psychopharmacol 26 5: 519-23. PMID 16974197. ^ Turkington D, Gill P. Jul-Aug 1989. Mania induced by lorazepam withdrawal: a report of two cases.. Journal of affective disorders. 17 1: 93-5. PMID 2525581. ^ Darcy L 19. Delirium tremens following withdrawal of nitrazepam. Med J Aust 2 8: 450. PMID 5086307. ^ Berezak A; Weber M, Hansmann J, Tulasne PA, Laporte B, Ould Ouali A 1984. Physical dependence on benzodiazepines in traumatology. Ann Fr Anesth Reanim 3 5: 383-4. PMID 6149713. ^ CSM 2007. Hypnotics and anxiolytics. British National Formulary. Retrieved on Sep 13, 2007. ^ Hood, HM; Metten P, Crabbe JC, Buck KJ. 2006. Fine mapping of a sedative-hypnotic drug withdrawal locus on mouse chromosome 11.. Genes, brain, and behavior. 51: 1-10. doi:10.1111/j.1601-183X.2005.00122.x. PMID 16436183. ^ Kitabayashi Y, Ueda H, Narumoto J, et al 2001. Chronic high-dose nitrazepam dependence 123I-IMP SPECT and EEG studies. Addict Biol 6 3: 257-261. doi:10.1080/13556210120056507. PMID 11900604. ^ McConnell JG May 2008. Benzodiazepine tolerance, dependency, and withdrawal syndromes and interactions with fluoroquinolone antimicrobials. British Journal of General Practice 58 550: 365-366. Royal College of General Practitioners. doi:10.3399/bjgp08X280317. ^ Unseld E; Ziegler G, Gemeinhardt A, Janssen U, Klotz U jul 1990. Possible interaction of fluoroquinolones with the benzodiazepine-GABAA-receptor complex. Br J Clin Pharmacol 58 1: 63-70. PMID 2167717. ^ Committee on Safety of Medicines 2007. Hypnotics and anxiolytics. British National Formulary. Retrieved on Sep 17, 2007. ^ Tagashira E; Hiramori T, Urano T, Nakao K, Yanaura S. Oct 1981. Enhancement of drug withdrawal convulsion by combinations of phenobarbital and antipsychotic agents.. Jpn J Pharmacol. 31 5: 689-99. doi:10.1254/jjp.31.689. PMID 6118452. ^ Zitman FG; Couvée JE Apr 2001. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry 178: 317-24. PMID 11282810. ^ Higgitt A; Fonagy P, Lader M 1988. The natural history of tolerance to the benzodiazepines. Psychol Med Monogr Suppl 13: 1-55. PMID 2908516. ^ DR JG McConnell 6. The Clinicopharmacotherapeutics of Benzodiazepine and Z drug dose Tapering Using Diazepam. BCNC. ^ Strang J et al Jul 1993. In Benzodiazepine Dependence.. Oxford Medical Publications 23: 128-42. ^ O'Connor RD 1993. Benzodiazepine dependence--a treatment perspective and an advocacy for control. NIDA Res Monogr 131: 266-9. PMID 8105385. ^ Professor C Heather Ashton 2004. Protracted withdrawal symptoms from benzodiazepines. ^ Ashton CH Mar 1995. Protracted Withdrawal From Benzodiazepines: The Post-Withdrawal Syndrome. Psychiatric Annals 25 3: 174-179. benzo.org.uk. ^ Modell JG Mar-Apr 1997. Protracted benzodiazepine withdrawal syndrome mimicking psychotic depression PDF. Psychosomatics 38 2: 160-1. Psychiatry Online. PMID 9063050. ^ Busto U; Fornazzari L, Naranjo CA Oct 1988. Protracted Tinnitus after Discontinuation of Long-Term Therapeutic Use of Benzodiazepines. J Clin Psychopharmacol 8 5: 359-62. doi:10.1097/00004714-198810000-00010. PMID 2903182. ^ Higgitt A; Fonagy P, Toone B, Shine P Aug 1990. The prolonged benzodiazepine withdrawal syndrome: anxiety or hysteria?. Acta Psychiatr Scand. 82 2: 165-8. doi:10.1111/j.1600-0447.1990.tb01375.x. PMID 1978465. ^ Roche USA Oct 2007. Romazicon PDF. Roche Pharmaceuticals USA. ^ Professor Malcolm Lader 1992. A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. Journal of Psychopharmacology. ^ Morgan K; Dixon S, Mathers N, Thompson J, Tomeny M. Feb 2004. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. PDF. Health Technol Assess. 8 8: 1-68. National Institute for Health Research. PMID 14960254. ^ Gerra G; Zaimovic A, Giusti F, Moi G, Brewer C Oct 2002. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study. Addict Biol 7 4: 385-95. doi:10.1080/1355621021000005973. PMID 14578014. External links Benzodiazepines: How they work and how to withdraw by Professor Heather Ashton Benzodiazepine withdrawal syndrome at the Open Directory Project v d e Benzodiazepines N05BA, N05CD 1,4-Benzodiazepines Bromazepam Camazepam Chlordiazepoxide Cinolazepam Clonazepam Clorazepate Cyprazepam Delorazepam Diazepam Doxefazepam Elfazepam Ethyl loflazepate Fletazepam Fludiazepam Fosazepam Flunitrazepam Flurazepam Flutoprazepam Gidazepam Halazepam Iclazepam Lorazepam Lormetazepam Meclonazepam Medazepam Menitrazepam Metaclazepam Nimetazepam Nitrazepam Nordazepam Oxazepam Phenazepam Pinazepam Pivoxazepam Prazepam Quazepam QH-II-66 Reclazepam Sulazepam Temazepam Tetrazepam Uldazepam Triazolobenzodiazepines Adinazolam Alprazolam Estazolam Triazolam Zapizolam Imidazobenzodiazepines Bretazenil Flumazenil Imidazenil Loprazolam Midazolam Ro15-4513 Ro48-6791 Oxazolobenzodiazepines Cloxazolam Flutazolam Haloxazolam Mexazolam Oxazolam Thienobenzodiazepines Brotizolam Clotiazepam Etizolam 1,5-Benzodiazepines Arfendazam Clobazam Lofendazam Triflubazam 2,3-Benzodiazepines Girisopam GYKI-52895 Nerisopam Tofisopam Benzodiazepine Prodrugs Avizafone Rilmazafone Others Bentazepam Ketazolam Razobazam Premazepam Tifluadom Zolazepam v d e WHO ICD-10 mental and behavioral disorders F · 290-319 Neurological/symptomatic Dementia Alzheimer's disease, multi-infarct dementia, Pick's disease, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, AIDS dementia complex, Frontotemporal dementia, Elopement, Sundowning, Wandering · Delirium · Post-concussion syndrome · Organic brain syndrome Psychoactive substance alcohol drunkenness, alcohol dependence, alcoholic hallucinosis, Alcohol withdrawal, delirium tremens, Korsakoff's syndrome, alcohol abuse · opioids opioid dependency · sedative/hypnotic benzodiazepine withdrawal · cocaine cocaine dependence · general Intoxication, Drug abuse, Physical dependence, Withdrawal Psychotic disorder Schizophrenia disorganized schizophrenia · Schizophreniform disorder · Schizotypal personality disorder · Delusional disorder · Folie à deux · Schizoaffective disorder Mood affective Mania · Bipolar disorder · Clinical depression · Cyclothymia · Dysthymia Neurotic, stress-related and somatoform Anxiety disorder Agoraphobia, Panic disorder, Panic attack, Generalized anxiety disorder, Social anxiety, Social phobia · OCD · Acute stress reaction · PTSD · Adjustment disorder · Conversion disorder Ganser syndrome · Somatoform disorder Somatization disorder, Body dysmorphic disorder, Hypochondriasis, Nosophobia, Da Costa's syndrome, Psychalgia · Neurasthenia Physiological/physical behavioral Eating disorder: Anorexia nervosa · Bulimia nervosa Sleep disorder: Dyssomnia Hypersomnia, Insomnia · Parasomnia REM behavior disorder, Night terror · Nightmare Sexual dysfunction: Erectile dysfunction · Premature ejaculation · Vaginismus · Dyspareunia · Hypersexuality · Female sexual arousal disorder Postpartum depression · Postnatal psychosis Adult personality and behavior Personality disorder · Passive-aggressive behavior · Kleptomania · Trichotillomania · Voyeurism · Factitious disorder · Munchausen syndrome · Ego-dystonic sexual orientation · Fetishism Mental retardation Mental retardation Psychological development developmental disorder Specific: speech and language expressive language disorder, aphasia, expressive aphasia, receptive aphasia, Landau-Kleffner syndrome, lisp · Scholastic skills dyslexia, dysgraphia, Gerstmann syndrome · Motor function developmental dyspraxia Pervasive: Autism · Rett syndrome · Asperger syndrome Behavioral and emotional, childhood and adolescence onset ADHD · Conduct disorder · Oppositional defiant disorder · Separation anxiety disorder · Selective mutism · Reactive attachment disorder · Tic disorder · Tourette syndrome · Speech stuttering · cluttering Retrieved from http://en..org/wiki/Benzodiazepine_withdrawal_syndrome Categories: Pharmacology | Drug addiction | Drug rehabilitation Views Article Discussion this page History Personal tools Log in / create account Navigation Main page Contents Featured content Current events Random article Search Go Search Interaction Community portal Recent changes Contact Donate to Help Toolbox What links here Related changes Upload file Special pages Printable version Permanent link Cite this page This page was last modified on 20 August 2008, at 10:43
39 Reasons to Drink Acai Juice Every Day
What is MonaVie - Watch the 8-minute video
Discovering MonaVie Video
The Power of You Video
Effects of MonaVie Active on Antioxidant Capacity in Humans
Log into your Wholesale MonaVie Account
So many of us do not eat a balanced diet, get enough sleep, have too much stress, or are impacted with toxins and pollutants. Drinking 2 ounces of MonaVie twice a day will help your body detoxify as well as build your immune system. Its the smartest thing you can do for yourself, so start today. Buying MonaVie through our company guarantees you support 7 days a week and, if you would like to share MonaVie with your family and friends we will guide you from start to finish.
1. Click on Enroll Now (30 - 55% off retail price)
2. Pay $39 for your Wholesale ID number.
3. NO minimum order required.
4. MonaVie is delivered to your door in 3 to 5 days.